Qiagen N.V.

Qiagen N.V.

QGEN

$43.69

Updated: 23/09/2026, 12:34:43

Market Cap
$9.01B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
NL
Stock valuation chart
One-year closing share-price history for QGEN
Company Profile

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

USD
NYSE
CEO: Jon Pratt
Employees: 5,500
https://www.qiagen.com
Asset Summaries
Latest generated summaries for QGEN

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for QGEN.
Share price
$43.69
Market cap
$9.01B
Exchange
NYSE
Currency
USD
CEO
Jon Pratt
Employees
5,500
IPO date
28/06/1996
Beta
0.626
Last dividend
$0.00
Day range
$43.63 – $44.47
52-week range
$32.53 – $57.82
1-day performance
-2.43%
1-year performance
34.31%
Current drawdown (1Y)
-24.44%
CIK
0001015820
CUSIP
N/A
ISIN
NL0015002SN0
Created
07/12/2025, 13:52:51
Last update
23/09/2026, 12:34:43

Track Qiagen N.V. with an AI analyst

See which prediction-market events move QGEN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to QGEN from your Railway `news_articles` table.

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

Business Wire • STOCK • 15/06/2026, 03:30:00

A Look at Qiagen NV (QGEN) After 4.2% Gain -- GF Value $52.66 vs Price $37.75

GuruFocus • STOCK • 09/06/2026, 21:52:00

Qiagen N.V. (QGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 03/06/2026, 17:12:01

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

GlobeNewsWire • STOCK • 02/06/2026, 19:41:00

Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?

Zacks Investment Research • STOCK • 29/05/2026, 12:20:34

QIAGEN Business Breakdown and Growth Drivers for 2026

Zacks Investment Research • STOCK • 28/05/2026, 13:01:28

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

GlobeNewsWire • STOCK • 26/05/2026, 19:35:00

QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.

GlobeNewsWire • STOCK • 21/05/2026, 22:00:00

QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform

Zacks Investment Research • STOCK • 21/05/2026, 15:55:42

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

Business Wire • STOCK • 20/05/2026, 18:05:00

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

PRNewsWire • STOCK • 15/05/2026, 00:20:00

QGEN SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

GlobeNewsWire • STOCK • 14/05/2026, 21:00:00